STAAR Surgical Company - Common Stock (STAA)
18.17
0.00 (0.00%)
Staar Surgical Company is a pioneering developer, manufacturer, and marketer of implantable miniature lenses, primarily used in vision correction procedures
Specializing in advanced ophthalmic technologies, the company focuses on innovative solutions for conditions such as myopia and presbyopia. Staar Surgical aims to enhance patient satisfaction and visual outcomes by providing high-quality, innovative products that are designed to improve the overall eye health and well-being of individuals seeking surgical options for improved eyesight. Through its commitment to research and development, the company continues to advance the field of vision correction and expand its global presence in the ophthalmic medical device market.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQSTAA) and the best and worst performers in the medical devices & supplies - specialty industry.
Via StockStory · February 28, 2025

Keep an eye on the top gainers and losers in Wednesday's session, as they reflect the most notable price movements.
Via Chartmill · February 12, 2025

Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.
Via Chartmill · February 12, 2025

Is STAAR SURGICAL CO (NASDAQSTAA) on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill · January 23, 2025

Despite its growth, STAAR SURGICAL CO (NASDAQSTAA) remains within the realm of affordability.
Via Chartmill · January 14, 2025

Staar Surgical posted a Q4 2024 revenue decline due to weak China sales. The company plans cost-cutting measures.
Via Benzinga · February 12, 2025

Via Benzinga · February 12, 2025

Via Benzinga · February 12, 2025

Via Benzinga · February 12, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · February 11, 2025

STAAR SURGICAL CO (NASDAQSTAA), a growth stock which is not overvalued.
Via Chartmill · December 24, 2024

Investors should take note of NASDAQ:STAA, a growth stock that remains attractively priced.
Via Chartmill · November 6, 2024

Via Benzinga · February 12, 2025

STAAR SURGICAL CO was identified as a growth stock that isn't overvalued. NASDAQ:STAA is excelling in various growth indicators while maintaining a solid financial footing.
Via Chartmill · February 5, 2025

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Via Benzinga · December 2, 2024

Investors seeking growth at a reasonable cost should explore STAAR SURGICAL CO (NASDAQSTAA).
Via Chartmill · November 29, 2024

Looking for growth without the hefty price tag? Consider STAAR SURGICAL CO (NASDAQSTAA).
Via Chartmill · October 9, 2024

Don't overlook NASDAQ:STAA—a stock with solid growth prospects and a reasonable valuation.
Via Chartmill · September 5, 2024

Via Benzinga · August 8, 2024

STAA stock results show that Staar Surgical missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 7, 2024

Via Benzinga · July 15, 2024